A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Abstract : The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine kinase inhibitor of the FGFR/VEGFR/PDFGR pathways)/fulvestrant combination.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-02089814
Contributor : Mouniati Colo <>
Submitted on : Thursday, April 4, 2019 - 11:00:51 AM
Last modification on : Saturday, April 6, 2019 - 1:05:08 AM

Links full text

Identifiers

Collections

Citation

F Campone, F Bachelot, F. Penault-Llorca, F Pallis, F Agrapart, et al.. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩. ⟨hal-02089814⟩

Share

Metrics

Record views

19